...
首页> 外文期刊>The Laryngoscope: A Medical Journal for Clinical and Research Contributions in Otolaryngology, Head and Neck Medicine and Surgery, Facial Plastic and Reconstructive Surgery .. >Growth suppression of human laryngeal squamous cell carcinoma by adenovirus-mediated tissue factor pathway inhibitor gene 2.
【24h】

Growth suppression of human laryngeal squamous cell carcinoma by adenovirus-mediated tissue factor pathway inhibitor gene 2.

机译:腺病毒介导的组织因子途径抑制剂基因2抑制人喉鳞状细胞癌的生长。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: The purpose of this study was to explore the inhibiting role of adenoviral-mediated (Ad)-tissue factor pathway inhibitor (TFPI)-2 gene in the growth of laryngeal squamous cell carcinoma (LSCC). STUDY DESIGN: The nude mice bearing LSCC were prepared by intracutaneous injection of Hep-2 cell. Gene therapy was performed by injecting adenoviruses carrying TFPI-2 gene around tumors in the animal model. METHODS: Eighteen nude mice bearing Hep-2 cell tumor were randomly separated into the treated group and control group. The former were injected with recombinant adenovirus Ad-TFPI-2 around the tumor, and the later were injected with equivalent Ad-LacZ. After treatment, differences of tumor weight, volume, and ultrastructure of tumor cells between these two groups were observed by measuring and using transmission electron microscope. Apoptosis in Hep-2 xenotransplants was detected using the terminal deoxy-transferase-mediated dUTP nick end labeling. In addition, the expressions of TFPI-2 protein andproliferating cell nuclear antigen (PCNA) in tumor tissues were detected using Western blot and immunohistochemistry, respectively. RESULTS: The average weight and volume of tumor in the treated group were significantly lower than that in the control group (P < .01). The PCNA index was obviously lower in the tumors treated group than that in the control group (P < .01). In addition, cell apoptosis was observed in xenotransplants of the treated group but not in the control group. CONCLUSION: Peritumor injection of Ad-TFPI-2 can inhibit growth of LSCC in nude mice model, and TFPI-2 might be a desirable gene for gene therapy in LSCC.
机译:目的:探讨腺病毒介导的(Ad)组织因子途径抑制剂(TFPI)-2基因在喉鳞状细胞癌(LSCC)生长中的抑制作用。研究设计:通过皮内注射Hep-2细胞制备了具有LSCC的裸鼠。通过在动物模型的肿瘤周围注射携带TFPI-2基因的腺病毒进行基因治疗。方法:将18只Hep-2细胞瘤裸鼠随机分为治疗组和对照组。前者在肿瘤周围注射重组腺病毒Ad-TFPI-2,而后者则注射等效的Ad-LacZ。治疗后,通过测量和使用透射电子显微镜观察两组之间的肿瘤重量,体积和肿瘤细胞超微结构的差异。使用末端脱氧转移酶介导的dUTP缺口末端标记检测了Hep-2异种移植物中的凋亡。此外,分别用蛋白质印迹法和免疫组织化学法检测了肿瘤组织中TFPI-2蛋白和增殖细胞核抗原(PCNA)的表达。结果:治疗组的平均肿瘤重量和体积均显着低于对照组(P <.01)。肿瘤治疗组的PCNA指数明显低于对照组(P <.01)。另外,在治疗组的异种移植物中观察到细胞凋亡,而在对照组中未观察到。结论:Ad-TFPI-2经皮腔注射可抑制裸鼠模型LSCC的生长,TFPI-2可能是LSCC基因治疗的理想基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号